Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as F18 FBPA Injection
F18 FBPA · 1 trial · 1 indication
Safety: To evaluate the safety profile of F18 FBPA, all cohorts will undergo safety monitoring for up to one week following the F18 FBPA PET/CT scan. Monitoring will include routine assessments of adverse events (AEs), physical examinations, and vital signs. Diagnostic efficacy: To assess the diagnostic efficacy of F18 FBPA PET/CT by quantifying tracer uptake (SUVmax, SUVmean and SUVpeak), aiming to determine the minimum effective dose and optimal imaging timepoint.
| Arm | Type | Description |
|---|---|---|
| F18 FBPA Injection | EXPERIMENTAL | Single arm treated by F18 FBPA Injection only |
| Name | Type | Description |
|---|---|---|
| F18 FBPA Injection | DRUG | F18 FBPA (4-Borono-2-\[18F\]fluoro-L-phenylalanine) is a radiolabeled phenylalanine analog used in positron emission tomography (PET) for tumor imaging. Its uptake is mainly facilitated by the L-type amino acid transporter 1 (LAT1), which is commonly overexpressed in malignant tumors. This selective transport mechanism allows F18 FBPA to accumulate preferentially in tumor tissues rather than in normal tissues. Once taken up by cells, the fluorine-18 isotope emits positrons, enabling accurate visualization of tracer distribution through PET imaging. |
Inclusion Criteria: 1. Subject aged 18-80 (inclusive). 2. Histopathological confirmed diagnosis of a solid tumor (including but not limited to osteogenic sarcoma, brain tumors, head and neck cancer, lung cancer, breast cancer, or colorectal cancer). 3. At least one measurable lesion identified on p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
F18 FBPA is an investigational small molecule being studied for use in solid tumors. It is a diagnostic imaging agent evaluated in PET/CT imaging to assess its safety and diagnostic performance in patients with solid tumors. The drug is currently in Phase 1 clinical development and is not yet approved.
F18 FBPA is a diagnostic imaging agent used in PET/CT scans. It is designed to visualize solid tumors, though its specific molecular target is not disclosed. The drug is being studied to evaluate its safety and diagnostic performance in patients with solid tumors.
F18 FBPA is being developed by Heron Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol HRTX. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and diagnostic performance in solid tumors.
F18 FBPA is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate the safety and diagnostic performance of F18 FBPA PET/CT imaging in solid tumors.
F18 FBPA is being studied in one active Phase 1 clinical trial with the identifier NCT07691775. The trial, titled 'A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors,' is recruiting 30 participants in Taiwan. It is an uncontrolled, non-randomized study open to adults aged 18 years and older.
Yes, F18 FBPA is also known as F18 FBPA Injection. Both names refer to the same investigational drug being developed by Heron Therapeutics, Inc. for use in PET/CT imaging of solid tumors. The drug is currently in Phase 1 clinical trials.